Human papillomaviruses (HPV) are the etiologic agents of cancer of the uterine cervix and several other neoplasias. Detection of HPV infection will improve the sensitivity of primary and secondary screening of cervical cancer. The clinical indications for the use of HPV tests will have to consider the natural history of HPV infection and diseases, and the multiplicity of types involved. Signal amplification HPV DNA tests detect several high-risk HPV types, are standardized, commercially available and approved for clinical use. Nucleic acid amplification techniques are ideal methods for epidemiologic purposes since they minimize misclassification of HPV infection status and allow detection of infection with low viral burden. They are currently under evaluation for clinical use. PCR is the most widespread method for HPV typing, especially with the use of consensus primers and typing with reverse hybridization techniques. Novel promising HPV detection strategies are now proposed, such as HPV mRNA detection, and suspension or solid phase arrays. These novel techniques will have to be evaluated as stringently as actual assays in clinical studies. Although assays have been developed for the evaluation of viral load, viral integration and HPV polymorphism in molecular epidemiological studies, their role in clinical practice is not currently defined.

Keywords:
Cervical cancer screening, Detection, human papillomaviruses, Nucleic acid amplification, Signal amplification, Typing, human papillomaviruses
1.
Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–265.
2.
Wright TCJ, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201–222.
3.
Iftner T, Villa LL: Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr 2003;31:80–88.
4.
Gravitt PE, Coutlée F, Iftner T, Sellors J, Quint WGV: New Technologies in cervical cancer screening. Vaccine 2008;26(suppl 10):K42–K52.
5.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004;324:17–27.
6.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah K, Snidjers PJF, Meijer CJLM: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003;348:518–527.
7.
Coutlée F, de Ladurantaye M, Tremblay C, Vincelette J, Labrecque L, Roger M: An important proportion of genital samples submitted for Chlamydia trachomatis detection by PCR contain small amounts of cellular DNA as measured by beta-globin gene amplification. J Clin Microbiol 2000;38:2512–2515.
8.
Peyton CL, Schiffman M, Lorincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, Herrero R, Sherman ME, Wheeler CM: Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998;36:3248–3254.
9.
Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F: Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007;105:530–535.
10.
Tarkowski TA, Rajeevan MS, Lee DR, Unger ER: Improved detection of viral RNA isolated from liquid-based cytology samples. Mol Diagn 2001;6:125–130.
11.
Coutlée F, Rouleau D, Ferenczy A, Franco EL: Human papillomavirus testing. Can J Inf Dis 2005;16:83–91.
12.
Coutlée F, Mayrand MH, Provencher D, Franco E: The future of HPV testing in clinical laboratories and applied virology research. Clin Diag Virol 1997;8:123–141.
13.
Gravitt PE, van Doorn LJ, Quint W, Schiffman M, Hildesheim A, Glass AG, Rush BB, Hellman J, Sherman ME, Burk RD, Wang SS: Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J Clin Microbiol 2007;45:3245–3250.
14.
Lorincz A, Anthony J: Advances in HPV detection with hybrid capture. Papillomavirus Rep 2002;12:145–154.
15.
Kiviat NB: Human papillomavirus; in Murray PR (ed): Manual of Clinical Microbiology. American Society for Microbiology, Washington, 2002, pp 1070–1079.
16.
Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT: HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87–93.
17.
Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M: Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008;46:2595–2604.
18.
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095–1101.
19.
Hesselink AT, Bulkmans NWJ, Berkhof J, Lorincz AT, Meijer CJL, Snijders PJF: Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/GP6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006;44:3680–3685.
20.
Wright TCJ, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ: 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120–2129.
21.
Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M: Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol 2003;41:4022–4030.
22.
Solomon D, Schiffman M, Tarone R; ALTS Study Group: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293–299 (also see comments).
23.
Sherman ME, Schiffman M, Cox JT: Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102–107.
24.
The ALTS Group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesoins: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397–402.
25.
Ferenczy A, Franco E: Cervical-cancer screening beyond the year 2000. Lancet Oncology 2002;2:27–32.
26.
Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC: Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818–825.
27.
Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, Franco EL: Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006;119:615–623.
28.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579–1588.
29.
Meijer CJ, Snijders PJ, Castle PE: Clinical utility of HPV genotyping. Gynecol Oncol 2006;103:12–17.
30.
Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, van Doorn LJ, Porras C, Silva S, Gonzalez P, Bratti MC, Rodriguez AC, Castle P: Comparison of the SPF10-LiPA system to the hybrid capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol 2007;45:1447–1454.
31.
Bauer HM, Greer CE, Manos MM: Determination of genital human papillomavirus infection by consensus polymerase chain reaction amplification; in Herrington CS, McGee JOD (eds): Diagnostic Molecular Pathology, a Practical Approach. Oxford, IRL Press, 1992, pp 131–152.
32.
van Doorn LJ, Quint W, Kleter B, Molijn A, Colau B, Martin MT, Kravang-In, Torrez-Martinez N, Peyton CL, Wheeler CM: Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF10 line probe assay. J Clin Microbiol 2002;40:979–983.
33.
Gravitt P, Peyton CL, Alessi TQ, Wheeler C, Coutlée F, Hildesheim A, Schiffman M, Scott DR, Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357–361.
34.
Gillio-Tos A, De-Marco L, Ghisetti V, Snijders PJ, Segnan N, Ronco G, Merletti F: Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. J Clin Virol 2006;36:126–132.
35.
van den Brule AJC, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJLM, Snijders PJF: GP5+/GP6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779–787.
36.
Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay J, Schlagg P, Boyle S, Hankins C, Vézina D, Cote P, Macleod J, Voyer H, Forest P, Walmsley S, Franco EL: Enhanced detection and typing of human papillomavirus DNA in Anogenital Samples with PGMY primers and the Linear Array HPV genotyping test. J Clin Microbiol 2006;44:1998–2006.
37.
Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, Burk RD: PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997;35:1304–1310.
38.
Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M: Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008;46:109–117.
39.
van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ: Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J Clin Microbiol 2006;44:3122–3129.
40.
Castle PE, Porras C, Quint WG, Rodriguez AC, Schiffman M, Gravitt PE, Gonzalez P, Katki HA, Silva S, Freer E, van Doorn LJ, Jimenez S, Herrero R, Hildesheim A: Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol 2008;46:3437–3445.
41.
Jiang HL, Zhu HH, Zhou LF, Chen F, Chen Z: Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system. J Med Microbiol 2006;55:715–720.
42.
Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T: Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504–512.
43.
Nuovo GJ, Bartholomew D, Jung WW, Han IK, Um T, Grabarz DF, Lee DJ, McCabe RT: Correlation of Pap smear, cervical biopsy, and clinical follow-up with an HPV typing microarray system. Diagn Mol Pathol 2008;17:107–111.
44.
Gheit T, Billoud G, de Koning MN, Gemignani F, Forslund O, Sylla BS, Vaccarella S, Franceschi S, Landi S, Quint WG, Canzian F, Tommasino M: Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect Betapapillomavirus types. J Clin Microbiol 2007;45:2537–2544.
45.
Tempfer C, Grimm C, Harwanegg C, Huber M, Mueller MW, Buerkle B, Reinthaller A, Hefler LA: Frequency of 23 human papillomavirus types using DNA microarray in women with and without cytological anomalies. Anticancer Res 2007;27:1721–1726.
46.
Oh TJ, Kim CJ, Woo SK, Kim TS, Jeong DJ, Kim MS, Lee S, Cho HS, An S: Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. J Clin Microbiol 2004;42:3272–3280.
47.
Wahlstrom C, Iftner T, Dillner J, Dillner L: Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol 2007;79:1169–1175.
48.
Carozzi F, Bisanzi S, Sani C, Zappa M, Cecchini S, Ciatto S, Confortini M: Agreement between the Amplicor human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007;45:364–369.
49.
van Ham MA, Bakkers JM, Harbers GK, Quint WG, Massuger LF, Melchers WJ: Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche Amplicor HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 2005;43:2662–2667.
50.
Halfon P, Trepo E, Antoniotti G, Bernot C, Cart Lamy P, Khiri H, Thibaud D, Marron J, Martineau A, Penaranda G, Benmoura D, Blanc B: Prospective evaluation of the hybrid capture 2 and Amplicor human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance. J Clin Microbiol 2007;45:313–316.
51.
Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, Holladay EB, Kolk DP: A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007;13:2599–2605.
52.
Schutzbank TE, Jarvis C, Kahmann N, Lopez K, Weimer M, Yount A: Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J Clin Microbiol 2007;45:4067–4069.
53.
Peitsaro P, Johansson B, Syrjanen S: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002;40:886–891.
54.
Azizi N, Brazete J, Hankins C, Money D, Fontaine J, Koushik A, Rachlis A, Pourreaux K, Ferenczy A, Franco E, Coutlee F: Influence of HPV-16 E2 polymorphism on quantitation of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia. J Gen Virol 2008;89:1716–1728.
55.
De Marco L, Gillio-Tos A, Bonello L, Ghisetti V, Ronco G, Merletti F: Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. J Clin Virol 2007;38:7–13.
56.
Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P, Doeberitz MV: Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999;59:6132–6136.
57.
Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Durst M, Schneider A, Knebel Doeberitz M: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307–313.
58.
Giannoudis A, Herrington CS: Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 2001;193:295–302.
59.
Sichero L, Ferreira S, Trottier H, Duarte Franco E, Ferenczy A, Franco EL, Villa LL: High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007;120:1763–1768.
60.
Schiffman MH, Kiviat NB, Burk RD, Shah KV, Daniel RW, Lewis R, Kuypers J, Manos MM, Scott DR, Sherman ME, Kurman RJ, Stoler MH, Glass AG, Rush BB, Mielzynska I, Lorincz AT: Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol 1995;33:545–550.
61.
Kornegay JR, Roger M, Davies PO, Shepard AP, Guerrero NA, Lloveras B, Evens D, Coutlée F: International proficiency study of a consensus L1 PCR assay for the detection and typing of HPV DNA: accuracy, intralaboratory and interlaboratory agreement evaluation. J Clin Microbiol 2003;41:1080–1086.
62.
Pagliusi SR, Dillner J, Pawlita M, Quint WG, Wheeler CM, Ferguson M: Chapter 23: International standard reagents for harmonization of HPV serology and DNA assays – an update. Vaccine 2006;24(suppl 3):193–200.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.